|
시장보고서
상품코드
2088420
세포 증식 시장 : 제품 유형별, 기술별, 세포 유형별, 배양 시스템별, 용도별, 최종 사용자별 시장 예측(2026-2032년)Cell Expansion Market by Product Type, Technology, Cell Type, Culture System, Application, End User - Global Forecast 2026-2032 |
||||||
360iResearch
세포 증식 시장은 2032년까지 연평균 복합 성장률(CAGR) 15.80%로 성장이 전망되며, 568억 6,000만 달러 규모로 확대될 것으로 예측됩니다.
| 주요 시장 통계 | |
|---|---|
| 기준 연도 : 2025년 | 203억 6,000만 달러 |
| 추정 연도 : 2026년 | 231억 8,000만 달러 |
| 예측 연도 : 2032년 | 568억 6,000만 달러 |
| CAGR(%) | 15.80% |
세포 증식 시장 개요
세포 증식은 바이오의약품 제조, 재생의학, 세포 및 유전자 치료, 백신 개발, 면역종양학 및 중개연구 분야에서 핵심적인 기반 기술입니다. 이 시장은 재현성 있는 세포 증식, 생존율, 효능 및 오염 관리를 뒷받침하는 확장 가능한 세포 배양 시스템, 무혈청 및 이종 성분 무함유 배지, 일회용 바이오리액터, 폐쇄형 시스템을 통한 자동화, 그리고 고품질 시약에 대한 수요 증가에 힘입어 형성되고 있습니다.
세포 증식 분야의 획기적인 변화
세포 증식 분야는 개방형 수작업 연구 워크플로우에서 밀폐형 자동화 시스템으로, 디지털 모니터링이 가능하고 GMP를 준수하는 제조 생태계로 점차 전환되고 있습니다. 이러한 전환은 환자별 변동성과 채혈부터 투여까지의 짧은 시간으로 인해 견고한 공정 관리가 요구되는 자가 세포 치료법, 배치 규모가 커서 일관된 세포 표현형과 효능을 갖춘 확장 가능한 증식 플랫폼이 필요한 동종 세포 치료법에서 특히 중요합니다.
세포 증식에 대한 인공지능의 누적 영향
인공지능(AI)은 실험 설계, 공정 최적화, 품질 예측 및 제조 관련 의사결정을 개선함으로써 세포 증식을 촉진하는 실질적인 원동력이 되고 있습니다. AI 및 머신러닝 모델은 세포 수, 대사 산물 프로파일, 이미지, 유세포 분석, 바이오리액터 센서, 전자 배치 기록, 환경 모니터링 시스템 등에서 얻은 고차원 데이터를 분석하여, 기존의 통계적 기법으로는 감지하기 어려운 패턴을 식별할 수 있습니다.
세포 증식에 관한 주요 지역별 인사이트
중국, 일본, 한국, 인도, 싱가포르, 호주가 재생의학 연구, 바이오의약품 제조 및 임상시험 활동을 확대함에 따라 아시아태평양의 중요성이 커지고 있습니다. 중국은 바이오의약품 생산 능력을 대폭 확충하고 있으며, 면역세포 치료에 대한 연구에서도 계속해서 활발한 활동을 펼치고 있습니다. 일본은 확립된 재생의학 규제 체계의 혜택을 누리고 있습니다. 한국은 첨단 바이오의약품 및 세포 치료 분야 인프라에 대한 투자를 지속하고 있습니다. 인도는 비용 효율이 높은 바이오 생산 역량을 강화해 나가고 있습니다. 또한 호주는 강력한 병원 및 연구 네트워크를 통해 초기 단계의 임상 적용을 지원하고 있습니다.
세포 증식에 관한 주요 그룹의 인사이트
아세안(ASEAN)은 싱가포르의 바이오프로세스 생태계, 태국의 의료 혁신 프로그램, 말레이시아의 생명과학 기반 시설, 베트남의 확대되는 헬스케어 투자, 그리고 인도네시아의 헬스케어 시장 규모에 힘입어 제조 및 임상 연구의 거점으로 부상하고 있습니다. 이러한 추세에 따라, 해당 지역은 세포 배양용 소모품, 바이오프로세스 교육, 중개 연구, 그리고 향후 세포 치료제 제조를 위한 준비 측면에서 점점 더 중요한 위치를 차지하고 있습니다. GCC 국가들은 첨단 의료 인프라, 유전체학, 정밀의료, 전문 의료 및 현지 바이오 제조 분야에 투자하고 있으며, 의료의 다양화와 첨단 치료법에 대한 접근성에 중점을 둔 장기적인 국가 전략에서 세포 증식이 중요한 위치를 차지하고 있습니다.
세포 증식에 관한 주요 국가의 동향
미국은 FDA 규제 대상인 세포 및 유전자 치료 파이프라인, 대학 부속 의료 센터, 생명공학 분야 자금 지원, GMP 제조 거점, 그리고 위탁 개발 및 제조(CDMO) 역량이 집중되어 있어 전 세계 세포 증식 수요를 주도하고 있습니다. 캐나다는 정평이 나 있는 줄기세포 과학, 중개 연구, 그리고 민관 협력을 통한 바이오 제조 지원 이니셔티브에 기여하고 있습니다. 멕시코와 브라질은 임상 연구, 생물학적 제제에 대한 수요, 지역 의료의 현대화, 그리고 현지 바이오 제조 역량에 대한 관심이 높아짐에 따라 그 중요성이 커지고 있습니다.
업계 리더를 위한 실천적인 제안
업계 리더는 오염 위험을 줄이고, 배치 간 일관성을 높이며, GMP 문서화를 지원하고, 보다 견고한 정체성 관리(chain-of-identity) 및 보관 이력 관리(chain-of-custody)를 가능하게 하는 밀폐형이며 자동화되고 확장 가능한 세포 증식 플랫폼을 우선적으로 고려해야 합니다. 세포 치료제 개발자는 규모 확대, 기술 이전, 규제 당국에 대한 신청 과정에서 비용이 많이 드는 공정 비교 문제를 피하기 위해 개발 초기 단계에서 증식 기술을 선택해야 합니다.
조사 방법
본 요약본은 공개된 규제 데이터베이스, 임상시험 등록 정보, 동료 심사를 거친 논문, 정부 보건 데이터, 업계 정보, 특허 동향, 제조 관련 발표 및 바이오프로세스 동향에 대한 전문가들의 견해를 다각적으로 대조하는 체계적인 시장 조사 기법에 기반을 두고 있습니다. 주요 정보원으로는 일반적으로 FDA, EMA, WHO, ClinicalTrials.gov, 각국의 통계 기관, 공인된 특허 데이터베이스, 투자자용 공개 정보, 그리고 확립된 저장소에 수록된 과학 문헌 등이 있습니다.
결론
세포 증식 시장은 연구 지원 분야에서 차세대 의료를 위한 전략적 제조거점으로 전환되고 있습니다. 이러한 성장을 주도하고 있는 것은 세포 및 유전자 치료 파이프라인, 재생의학, 생물학적 제제 개발, 백신 연구, 면역종양학, 그리고 확장성이 뛰어나고 재현성이 높으며 규제를 준수하는 세포 배양 공정의 필요성입니다.
자주 묻는 질문
목차
제1장 서문
제2장 조사 방법
제3장 주요 요약
제4장 시장 개요
제5장 시장 인사이트
제6장 AI의 누적 영향(2026년)
제7장 세포 증식 시장 : 제품 유형별
제8장 세포 증식 시장 : 기술별
제9장 세포 증식 시장 : 세포 유형별
제10장 세포 증식 시장 : 배양 시스템별
제11장 세포 증식 시장 : 용도별
제12장 세포 증식 시장 : 최종 사용자별
제13장 세포 증식 시장 : 지역별
제14장 세포 증식 시장 : 그룹별
제15장 세포 증식 시장 : 국가별
제16장 경쟁 구도
제17장 기업 개요
AJY 26.07.22The Cell Expansion Market is projected to grow by USD 56.86 billion at a CAGR of 15.80% by 2032.
| KEY MARKET STATISTICS | |
|---|---|
| Base Year [2025] | USD 20.36 billion |
| Estimated Year [2026] | USD 23.18 billion |
| Forecast Year [2032] | USD 56.86 billion |
| CAGR (%) | 15.80% |
Cell Expansion Market Introduction
Cell expansion is a core enabling technology for biopharmaceutical manufacturing, regenerative medicine, cell and gene therapy, vaccine development, immuno-oncology, and translational research. The market is shaped by rising demand for scalable cell culture systems, serum-free and xeno-free media, single-use bioreactors, closed-system automation, and high-quality reagents that support reproducible cell growth, viability, potency, and contamination control.
Publicly observable demand signals remain strong: regulatory activity for cell and gene therapies continues to expand across FDA and EMA pathways, ClinicalTrials.gov lists thousands of active cell therapy-related studies globally, and biomanufacturing investment remains closely tied to advanced therapy medicinal products. As developers move from laboratory-scale workflows to clinical and commercial manufacturing, cell expansion solutions are increasingly evaluated on sterility assurance, process scalability, cost per dose, regulatory traceability, chain-of-identity control, and compatibility with good manufacturing practice standards.
Transformative Shifts in the Cell Expansion Landscape
The cell expansion landscape is shifting from open, manual, research-grade workflows toward closed, automated, digitally monitored, and GMP-aligned manufacturing ecosystems. This transition is especially important for autologous cell therapies, where patient-specific variability and short vein-to-vein timelines require robust process control, and for allogeneic approaches, where larger batch sizes demand scalable expansion platforms with consistent cell phenotype and potency.
Suppliers are differentiating through integrated portfolios that combine media, growth factors, cultureware, bioreactors, sensors, analytics, cell separation tools, and cryopreservation solutions. The industry is also moving toward serum-free, xeno-free, and chemically defined media to reduce variability and support regulatory acceptance. At the same time, capacity constraints, skilled labor shortages, cold-chain complexity, and quality-control requirements are accelerating adoption of modular manufacturing, single-use assemblies, automated cell processing systems, and standardized digital batch documentation.
Cumulative Impact of Artificial Intelligence on Cell Expansion
Artificial intelligence is becoming a practical accelerator for cell expansion by improving experimental design, process optimization, quality prediction, and manufacturing decision-making. AI and machine learning models can analyze high-dimensional data from cell counts, metabolite profiles, imaging, flow cytometry, bioreactor sensors, electronic batch records, and environmental monitoring systems to identify patterns that are difficult to detect through conventional statistical methods.
The strongest near-term impact is in predictive process control, anomaly detection, media optimization, donor variability assessment, and release testing support. AI-enabled image analysis can improve consistency in confluence assessment and morphology tracking, while digital twins can help manufacturers simulate scale-up scenarios before committing costly GMP resources. However, adoption depends on validated data integrity, explainable models, cybersecurity, audit-ready documentation, and alignment with regulatory expectations for computerized systems, model lifecycle management, and quality-by-design manufacturing.
Key Regional Insights for Cell Expansion
Asia-Pacific is gaining importance as China, Japan, South Korea, India, Singapore, and Australia expand regenerative medicine research, biologics manufacturing, and clinical trial activity. China has built substantial biopharma capacity and remains highly active in immune cell therapy research; Japan benefits from an established regenerative medicine regulatory framework; South Korea continues to invest in advanced biologics and cell therapy infrastructure; India is strengthening cost-efficient biomanufacturing capabilities; and Australia supports early-phase clinical translation through strong hospital and research networks.
North America remains a leading hub because of the concentration of FDA-regulated clinical development, venture funding, academic medical centers, contract development and manufacturing organizations, and commercial cell therapy launches in the United States, with Canada contributing recognized stem cell science, translational research, and biomanufacturing initiatives. Latin America is developing gradually, led by Brazil and Mexico, where public health demand, clinical research networks, improving biologics capacity, and university-led biomedical programs support future adoption of cell expansion technologies.
Europe benefits from EMA oversight, advanced therapy medicinal product expertise, and strong clusters in Germany, France, the United Kingdom, Italy, Spain, the Netherlands, Belgium, Switzerland, and the Nordics. The Middle East is investing in biomedical innovation, precision medicine, specialty hospitals, genomics, and local production ambitions, particularly in the Gulf. Africa is earlier-stage but strategically relevant as vaccine manufacturing programs, academic partnerships, regional bioprocessing initiatives, and public health-focused biotechnology capacity build the foundation for long-term cell culture and cell expansion adoption.
Key Group Insights for Cell Expansion
ASEAN is emerging as a manufacturing and clinical research corridor, supported by Singapore's bioprocessing ecosystem, Thailand's medical innovation programs, Malaysia's life sciences base, Vietnam's expanding healthcare investment, and Indonesia's healthcare scale. These dynamics make the region increasingly relevant for cell culture consumables, bioprocess training, translational research, and future cell therapy manufacturing readiness. The GCC is investing in advanced healthcare infrastructure, genomics, precision medicine, specialty care, and local biomanufacturing ambitions, making cell expansion relevant to long-term national strategies focused on healthcare diversification and advanced therapeutics access.
The European Union provides a harmonized regulatory environment for advanced therapy medicinal products, while national centers of excellence support process development, quality systems, and GMP translation. BRICS countries represent a significant demand base because of large patient populations, expanding biologics manufacturing, academic research activity, and public-sector interest in local production. G7 markets continue to lead in funding intensity, regulatory maturity, intellectual property generation, clinical trial infrastructure, and commercial adoption of advanced therapies. NATO countries overlap heavily with mature biopharma economies, where supply chain resilience, sterile manufacturing, critical reagent access, and domestic bioproduction capacity are increasingly strategic priorities.
Key Country Insights for Cell Expansion
The United States leads global cell expansion demand through its concentration of FDA-regulated cell and gene therapy pipelines, academic medical centers, biotech funding, GMP manufacturing sites, and contract development and manufacturing capacity. Canada contributes recognized stem cell science, translational research, and supportive public-private biomanufacturing initiatives. Mexico and Brazil are building relevance through clinical research, biologics demand, regional healthcare modernization, and growing interest in local biomanufacturing capabilities.
In Europe, the United Kingdom, Germany, France, Italy, and Spain combine advanced clinical research, hospital networks, regulatory experience, and GMP manufacturing expertise, while Russia maintains scientific capacity but faces constraints linked to sanctions, technology access, supply chain limitations, and capital flows. China is one of the most active countries in cell therapy clinical development and manufacturing scale-up. India is advancing through cost-efficient biomanufacturing, stem cell research, vaccine and biologics expertise, and a growing biotech base. Japan benefits from regenerative medicine policy experience and strong translational research; Australia offers robust clinical trial infrastructure and biomedical research quality; and South Korea is a leading Asian hub for biologics, biosimilars, regenerative medicine, and cell therapy manufacturing.
Actionable Recommendations for Industry Leaders
Industry leaders should prioritize closed, automated, and scalable cell expansion platforms that reduce contamination risk, improve batch consistency, support GMP documentation, and enable stronger chain-of-identity and chain-of-custody control. Developers of cell therapies should select expansion technologies early in development to avoid costly process comparability challenges during scale-up, technology transfer, and regulatory submission.
Manufacturers should invest in serum-free, xeno-free, and chemically defined media; real-time analytics; validated digital systems; and quality-by-design frameworks to improve reproducibility and reduce cost of goods. Partnerships with contract manufacturers, academic medical centers, automation vendors, reagent suppliers, and analytics providers can shorten development timelines. Leaders should also build resilient supply chains for critical reagents, single-use components, cytokines, growth factors, cultureware, and consumables, while maintaining qualified dual sourcing where quality, continuity, and regulatory requirements allow.
Research Methodology
This executive summary is based on a structured market research methodology that triangulates public regulatory databases, clinical trial registries, peer-reviewed publications, government health data, trade information, patent activity, manufacturing announcements, and expert interpretation of bioprocessing trends. Key sources typically include FDA, EMA, WHO, ClinicalTrials.gov, national statistics agencies, recognized patent databases, public investor disclosures, and scientific literature indexed in established repositories.
The methodology evaluates demand drivers, technology adoption, manufacturing constraints, regulatory dynamics, regional capacity, supply chain resilience, and competitive positioning without relying on unsupported projections. Findings are validated through cross-source comparison to reduce dependence on single-point evidence. Market interpretation emphasizes verified developments, observable investment patterns, approved therapy trends, clinical pipeline activity, regulatory requirements, and practical manufacturing needs across research, clinical, and commercial cell expansion workflows.
Conclusion
The cell expansion market is transitioning from a research-support segment into a strategic manufacturing foundation for next-generation medicine. Growth is being driven by cell and gene therapy pipelines, regenerative medicine, biologics development, vaccine research, immuno-oncology, and the need for scalable, reproducible, and compliant cell culture processes.
Competitive advantage will increasingly depend on automation, closed processing, AI-enabled analytics, defined media systems, validated quality controls, and regional manufacturing resilience. Organizations that align technology selection with regulatory expectations, clinical scalability, sterility assurance, and cost-of-goods discipline will be best positioned to capture value as cell-based therapies move from specialized treatment centers toward broader commercial access.
Table of Contents
1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Definition
- 1.3. Market Segmentation & Coverage
- 1.4. Years Considered for the Study
- 1.5. Currency Considered for the Study
- 1.6. Language Considered for the Study
- 1.7. Key Stakeholders
2. Research Methodology
- 2.1. Introduction
- 2.2. Research Design
- 2.2.1. Primary Research
- 2.2.2. Secondary Research
- 2.3. Research Framework
- 2.3.1. Qualitative Analysis
- 2.3.2. Quantitative Analysis
- 2.4. Market Size Estimation
- 2.4.1. Top-Down Approach
- 2.4.2. Bottom-Up Approach
- 2.5. Data Triangulation
- 2.6. Research Outcomes
- 2.7. Research Assumptions
- 2.8. Research Limitations
3. Executive Summary
- 3.1. Introduction
- 3.2. CXO Perspective
- 3.3. Market Size & Growth Trends
- 3.4. Market Share Analysis, 2025
- 3.5. FPNV Positioning Matrix, 2025
- 3.6. New Revenue Opportunities
- 3.7. Next-Generation Business Models
- 3.8. Industry Roadmap
4. Market Overview
- 4.1. Introduction
- 4.2. Industry Ecosystem & Value Chain Analysis
- 4.2.1. Supply-Side Analysis
- 4.2.2. Demand-Side Analysis
- 4.2.3. Stakeholder Analysis
- 4.3. Market Dynamics
- 4.3.1. Key Drivers
- 4.3.2. Key Restraints
- 4.3.3. Key Opportunities
- 4.3.4. Key Challenges
- 4.4. Porter's Five Forces Analysis
- 4.5. PESTLE Analysis
- 4.6. Market Outlook
- 4.6.1. Near-Term Market Outlook (0-2 Years)
- 4.6.2. Medium-Term Market Outlook (3-5 Years)
- 4.6.3. Long-Term Market Outlook (5-10 Years)
- 4.7. Go-to-Market Strategy
5. Market Insights
- 5.1. Consumer Insights & End-User Perspective
- 5.2. Consumer Experience Benchmarking
- 5.3. Opportunity Mapping
- 5.4. Distribution Channel Analysis
- 5.5. Pricing Trend Analysis
- 5.6. Regulatory Compliance & Standards Framework
- 5.7. ESG & Sustainability Analysis
- 5.8. Disruption & Risk Scenarios
- 5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Cell Expansion Market, by Product Type
- 7.1. Cell Culture Media
- 7.1.1. Serum Based Media
- 7.1.2. Serum Free Media
- 7.2. Reagents
- 7.2.1. Buffers
- 7.2.2. Antibiotics
- 7.3. Bioreactors
- 7.3.1. Stirred Tank Bioreactors
- 7.3.2. Wave Bioreactors
- 7.3.3. Hollow Fiber Bioreactors
- 7.4. Cell Counters
- 7.5. Culture Vessels
8. Cell Expansion Market, by Technology
- 8.1. 2D Cell Culture
- 8.2. 3D Cell Culture
- 8.2.1. Spheroid
- 8.2.2. Organoid
- 8.3. Scaffold based Culture
- 8.3.1. Hydrogel
- 8.3.2. Polymer
- 8.4. Suspension Culture
- 8.5. Perfusion Systems
9. Cell Expansion Market, by Cell Type
- 9.1. Mammalian Cells
- 9.1.1. CHO Cells
- 9.1.2. HEK Cells
- 9.2. Stem Cells
- 9.3. Immune Cells
- 9.3.1. T Cells
- 9.3.2. NK Cells
- 9.3.3. Dendritic Cells
- 9.4. Microbial Cells
- 9.4.1. Bacteria
- 9.4.2. Yeast
- 9.5. Primary Cells
- 9.5.1. Hepatocytes
- 9.5.2. Fibroblasts
- 9.5.3. Endothelial
10. Cell Expansion Market, by Culture System
- 10.1. Open
- 10.2. Closed
- 10.3. Automated
11. Cell Expansion Market, by Application
- 11.1. Biopharmaceutical Production
- 11.1.1. Monoclonal Antibody Production
- 11.1.2. Recombinant Protein Production
- 11.2. Cell & Gene Therapy
- 11.3. Regenerative Medicine
- 11.3.1. Tissue Engineering
- 11.3.2. Organ Regeneration Research
- 11.4. Research & Development
- 11.5. Toxicology Testing
12. Cell Expansion Market, by End User
- 12.1. Academic Research Institutes
- 12.2. Biotechnology Companies
- 12.3. Contract Manufacturing Organizations
- 12.4. Pharmaceutical Companies
13. Cell Expansion Market, by Region
- 13.1. Asia-Pacific
- 13.2. North America
- 13.3. Latin America
- 13.4. Europe
- 13.5. Middle East
- 13.6. Africa
14. Cell Expansion Market, by Group
- 14.1. ASEAN
- 14.2. GCC
- 14.3. European Union
- 14.4. BRICS
- 14.5. G7
- 14.6. NATO
15. Cell Expansion Market, by Country
- 15.1. United States
- 15.2. Canada
- 15.3. Mexico
- 15.4. Brazil
- 15.5. United Kingdom
- 15.6. Germany
- 15.7. France
- 15.8. Russia
- 15.9. Italy
- 15.10. Spain
- 15.11. China
- 15.12. India
- 15.13. Japan
- 15.14. Australia
- 15.15. South Korea
16. Competitive Landscape
- 16.1. Market Concentration Analysis, 2025
- 16.1.1. Concentration Ratio (CR)
- 16.1.2. Herfindahl Hirschman Index (HHI)
- 16.2. Recent Developments & Impact Analysis, 2025
- 16.3. Product Portfolio Analysis, 2025
- 16.4. Benchmarking Analysis, 2025
17. Company Profiles
- 17.1. Agilent Technologies Inc
- 17.2. Allogene Therapeutics Inc
- 17.3. Becton Dickinson and Company
- 17.4. Bio-Techne Corporation
- 17.5. Cellectis SA
- 17.6. CellGenix GmbH
- 17.7. Corning Incorporated
- 17.8. Cytiva Uppsala AB
- 17.9. Danaher Corporation
- 17.10. Eppendorf SE
- 17.11. FUJIFILM Irvine Scientific Inc
- 17.12. GE HealthCare Technologies Inc
- 17.13. Getinge AB
- 17.14. HiMedia Laboratories Pvt Ltd
- 17.15. Kite Pharma Inc
- 17.16. Lonza Group AG
- 17.17. Merck KGaA
- 17.18. Miltenyi Biotec GmbH
- 17.19. PBS Biotech Inc
- 17.20. Promab Biotechnologies Inc
- 17.21. PromoCell GmbH
- 17.22. Repligen Corporation
- 17.23. Sartorius AG
- 17.24. STEMCELL Technologies Inc
- 17.25. Takara Bio Inc
- 17.26. Takara Bio USA Holdings Inc
- 17.27. Terumo Corporation
- 17.28. Thermo Fisher Scientific Inc
- 17.29. WuXi AppTec Co Ltd
